Table 1.
Characteristic |
N (%) |
|
---|---|---|
(n = 739) | ||
Age, years (n = 714) | ||
< 40 | 207 (29.0%) | |
40–59 | 435 (60.9%) | |
> 60 | 72 (10.1%) | |
Gender (n = 739) | ||
male | 238 (32.2%) | |
female | 501 (67.8%) | |
Comorbidities1 (n = 498) | 118 (23.7%) | |
Immunosupressive drugs (n = 511) | 19 (3.7%) | |
BMI (n = 467) | ||
< 20 | 32 (6.9%) | |
20–25 | 188 (40.2%) | |
> 25–30 | 167 (35.8%) | |
> 30 | 80 (17.1%) | |
Smoking (n = 510) | ||
yes | 167 (32.7%) | |
no | 343 (67.3%) | |
Regular physical exercise (n = 513) | ||
yes | 111 (21.6%) | |
no | 402 (78.4%) | |
SARS-CoV-2 infection2 (n = 739) | 72 (9.7 %) | |
before vaccination | 37 | |
before 1st sampling3 | 1 3 | |
before 2nd sampling4 | 3 | |
before 3rd sampling5 | 19 | |
Mild side effects post-vaccination (n = 510) | 269 (52.7%) |
n: the number of participants who answered this question; HCP: healthcare personnel; BMI: body mass index; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; RT-PCR: real-time polymerase chain reaction.
Co-morbidities included diabetes mellitus (26 HCP), autoimmune disorder (44 HCP), and other (57 HCP).
confirmed by RT-PCR.
after 2nd vaccine dose.
after first sampling and before third vaccine dose.
after second sampling and before third vaccine dose.